Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Non-Deal Roadshow (September 2019)
20 slides from Neurizon Therapeutics's roadshow presentation, Sep 9, 2019
Slide 1: Investor Roadshow Presentation September 2019
ASX: PAA ACN 094 006 023 Investor Roadshow Presentation September 2019 1
Slide 2: Corporate Structure
Corporate Structure 100% 100% Pitney Pharmaceuticals Limited Epichem Synthetic Medicinal Chemistry Pitney Pharmaceuticals Focus on Developing and Expected 2019-2020 sales A$4.2m repurposing a registered drug (Monepantel) in oncology Investor Presentation September 2019 2
Slide 3: Corporate Snapshot
Corporate Snapshot ASX Code: PAA Total Shares on Issue 280,221,192 Market Cap at $0.12 $33.6M Options (Unlisted) 56,895,412 Cash (as at 30 June 2019) $2.1M Debt (EFIC) $325K Top 20 Own 37% Epichem Revenue Forecast $4.2M Board/Exec Own 9.3% 2019-2020 Investor Presentation September 2019 3
Slide 4: Experienced Board & Management Team
Experienced Board & Management Team Dr. Roger Aston, Executive Chairman Sam Wright, Director & Company Secretary • > 30 years experience in the pharmaceutical and • > 20 years experience in biotech and healthcare. healthcare industries. • Extensive experience in relation to public company • Director
Slide 5: Mainstay of Cancer Treatment: Chemotherapy
CHEMOTHERAPY (Global Sales $52bln) MAINSTAY OF CANCER TREATMENT • Chemotherapy kills rapidly dividing cells • Typically tumour cells replicate more quickly than normal cells and this difference is harnessed in chemotherapy to selectively kill cancer • Side Effects during chemotherapy arise because n
Slide 6: A Unique Anticancer Paradigm: Monepantel in Oncology
MONEPANTEL (MPL) IN ONCOLOGY A UNIQUE ANTICANCER PARADIGM • VERY LOW TOXICITY • ALREADY REGISTERED AS A ON NORMAL CELLS VETERINARY MEDICINE • mTOR REGULATOR ACCESS TO • SIMPLER PATH TO ALLOWS HIGH REGISTRATION REGISTRATION DOSSIER FOR DOSE THERAPY SAFETY, TOXICOLOGY MANUFACTURE VALIDATION IN IN PLAC
Slide 7: MPL and Chemotherapy Comparatives
COMPARATIVES MPL AND CHEMOTHERAPY THE SINGLE MOST IMPORTANT LIMITATION OF CHEMOTHERAPY IS DOSE LIMITING TOXICITY ACTIVITY MPL CHEMOTHERAPY PROGRESSION FREE SURVIVAL ++++ ++ IMMUNOSUPPRESSION + ++++ HIGH DOSE TOXICITY + +++++ RESISTANCE ? ++++ REGRESSION ++ +++++ PharmAust Investor Presentation Septe
Slide 8: Risk Mitigation in Next Stage Development
RISK MITIGATION IN NEXT STAGE DEVELOPMENT TUMOUR MARKERS IN CANINES RECEIVING MPL HUMAN PROSTATE, LUNG SHOW SIGNIFICANCE IN AND BOWEL CANCER PROGRESSION FREE SIGNIFICANLY SUPPRESSED BY SURVIVAL MPL MPL PROGRESSION FREE CANINE TRIAL BEGINNING SURVIVAL AN FDA APPROVED NOW WILL BE BASIS TO ENDPOINT FOR
Slide 9: Background Summary
Background Summary • Lead product is Monepantel (MPL) – a repurposed drug already approved for Veterinary use by Elanco US Inc • PharmAust patented MPL as an anti-cancer drug • Clinical strategy targeting MPL for vet and human applications • Option Agreement with Elanco US Inc for veterinary cancer
Slide 10: Preparing for Pivotal Phase II Trial in Canine Cancer
Preparing for Pivotal Phase II Trial in Canine Cancer During 2019 KEY CLINICAL ENDPOINTS 1.Safety 2.Lack of Toxicity 3.Progression Free Survival 4.Regression 5.Administration by Owner at Home 6.Suppression of Tumour Markers Investor Presentation September 2019 10
Slide 11: Clinical Outcomes To Commercial Opportunities
Clinical Outcomes To Commercial Opportunities Pilot phase II (2017) in lymphoma trial in dogs Shows MPL effective at Progression-Free Survival Using poor formulation Extensive Reformulation Program: 2018 - 2019 Extensive Phase I Program During 2019 Establishes Establishes New, High Dose, Palatable T
Slide 12: Fast Track Strategy
Fast Track Strategy ON MARKET OPTION DRUG AGREEMENT NOW OWNED RESEARCHED BY ELANCO BY VOC & OTHERS Investor Presentation September 2019 12
Slide 13: >$2 Billion market for approved mTOR Drugs
>$2 Billion market for approved mTOR Drugs Drug Approved Indications Company 2016 Sales (US$m)1 Sirolimus Transplantation Pfizer 170 Transplantation Renal Cell Carcinoma Rapalogues Breast Cancer Novartis/Pfizer >2,000 (Afinitor/Torisel) Pancreatic Neuroendocrine Tumours Mantle Cell Lymphoma 1. Globa
Slide 14: Trends in Companion Animal Health Market (US:2016)
Trends in Companion Animal Health Market (US:2016) US Dog/Cat $ Total Pet Expenditure: $70b1 Populations (2016)1 Vet Care Expenditure $17b1 Pet drug market $10.2b in 20182 (8% CAGR) 94m 90m Willingness to pay more for treatment3 ($2K-$5K/treatment) 1. http://www.americanpetproducts.org/press_industr
Slide 15: Initial Market - Pets and Cancer
Initial Market -Pets and Cancer 1 in 4 dogs die of cancer - 6 million diagnosed annually in US Pets are living longer (50% dogs > 10 yrs often die of cancer) Significant unmet need for new oncology drugs (US$500m - USD$1b market) Side effects associated with products and treatments are limit
Slide 16: Elanco enters therapeutic oncology arena by purchase of Aratana
Elanco strategically enters therapeutic oncology arena by the purchase of Aratana Elanco Global No. 3 Animal Health Company Investor Presentation September 2019 16
Slide 17: Product Areas of Focus
Product Areas of Focus Elanco is an established leader with flagship brands and a global presence. They’re focused on investing and innovating in the animal health priorities that mean the most to their customers and the animals in their care. COMPANION ANIMAL FOOD ANIMAL Investor Presentation Septe
Slide 18: PharmAust – current status and next steps
PharmAust – current status and next steps • Successful rights issue completed earlier in year • Sufficient funds to complete Phase II in dogs as well as initiate clinical trials in humans • Successful micronisation and tablet manufacture • Phase II canine trial on dogs with lymphoma – commenced Sep
Slide 19: PharmAust Investor Presentation September 2019
PharmAust Investor Presentation September 2019 19
Slide 20: Disclaimer
Disclaimer This presentation has been prepared by PharmAust Limited (ASX: PAA) (ACN: 094 006 023) (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents
Neurizon Therapeutics — Non-Deal Roadshow (September 2019) on 6ix